{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-24-000041","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.376334+00:00","generated_at":"2026-06-05T12:22:23.602493+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pliant Therapeutics reports Q4 2023 net loss of $41.1M; positive bexotegrast data in PSC","bullets":["Net loss $41.1M vs $35.1M YoY; R&D expenses $33.2M (+32% YoY) driven by bexotegrast costs.","Cash $495.7M; expected to fund operations into H2 2026.","Positive 12-week data from 320 mg cohort of INTEGRIS-PSC: reduced ELF and PRO-C3, improved bile flow.","BEACON-IPF Phase 2b enrolling ~270 patients; 24-week PSC data expected mid-2024.","PLN-101095 Phase 1 solid tumors enrolling third cohort; DMD regulatory filing expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-24-000041","json":"https://secwatch.observer/filing/0001746473-24-000041.json","markdown":"https://secwatch.observer/filing/0001746473-24-000041.md","text":"https://secwatch.observer/filing/0001746473-24-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000041/0001746473-24-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000041/plrx-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:22:23.602493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b48b17aeb77c339ee6e4e19aed42642aa6c17af","claim":"PLIANT THERAPEUTICS, INC. reported fourth quarter ended December 31, 2023 results: net income Net loss was $41.1 million.","evidence_excerpt":"Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000041/0001746473-24-000041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Net income","value":"Net loss was $41.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}